Known targets — ChEMBL curated mechanism
MAP3K10MAP3K11MAP3K12MAP3K13MAP3K9
The experimentally established mechanism targets of Cep-1347. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K11 known ✓ | Q16584 | 14/20 | 1.00 |
| ▸ | MAP3K9 known ✓ | P80192 | 12/20 | 1.00 |
| ▸ | MAP3K10 known ✓ | Q02779 | 8/20 | 1.00 |
| ▸ | KDR | P35968 | 4/20 | 1.00 |
| ▸ | FLT1 | P17948 | 1/20 | 1.00 |
| ▸ | FLT4 | P35916 | 1/20 | 1.00 |
| ▸ | DLK1 | P80370 | 1/20 | 1.00 |
| ▸ | NTRK1 | P04629 | 8/20 | 0.93 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.74 |
| ▸ | PRKCG | P05129 | 3/20 | 0.74 |
| ▸ | PRKCB | P05771 | 3/20 | 0.74 |
| ▸ | PRKCA | P17252 | 3/20 | 0.74 |
| ▸ | PRKCH | P24723 | 3/20 | 0.74 |
| ▸ | PRKCI | P41743 | 3/20 | 0.74 |
| ▸ | PRKCE | Q02156 | 3/20 | 0.74 |
| ▸ | PRKCQ | Q04759 | 3/20 | 0.74 |
| ▸ | PRKCZ | Q05513 | 3/20 | 0.74 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.74 |
| ▸ | PRKD1 | Q15139 | 3/20 | 0.74 |
| ▸ | MYLK | Q15746 | 3/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cep-1347 SCHEMBL8263437 | 1.00 | MAP3K11 (1.00) | MAP3K11MAP3K9MAP3K10KDRFLT1 | |
| Cep-1347 SCHEMBL12047710 | 1.00 | MAP3K11 (1.00) | MAP3K11MAP3K9MAP3K10KDRFLT1 | |
| Cep-1347 SCHEMBL30198505 | 1.00 | MAP3K11 (1.00) | MAP3K11MAP3K9MAP3K10KDRFLT1 | |
| SCHEMBL13140134 | 0.97 | MAP3K11 (0.93) | MAP3K11MAP3K9MAP3K10KDRFLT1 | |
| SCHEMBL13142263 | 0.97 | MAP3K11 (0.93) | MAP3K11MAP3K9MAP3K10KDRFLT1 | |
| SCHEMBL12445000 | 0.95 | MAP3K11 (0.90) | MAP3K11MAP3K9MAP3K10KDRFLT1 | |
| SCHEMBL5964631 | 0.93 | MAP3K11 (0.86) | MAP3K11MAP3K9MAP3K10KDRFLT1 | |
| SCHEMBL29366906 | 0.91 | MAP3K11 (1.00) | MAP3K11MAP3K9MAP3K10KDRFLT1 | |
| SCHEMBL15289975 | 0.91 | MAP3K11 (1.00) | MAP3K11MAP3K9MAP3K10KDRFLT1 | |
| SCHEMBL13234118 | 0.90 | MAP3K11 (0.81) | MAP3K11MAP3K9MAP3K10KDRFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 344 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12364681-B2 | Combined MAPK and NAMPT inhibition for treatment of neuron degeneration | THE JOHNS HOPKINS UNIVERSITY (US) | 2025-07-22 | — | — | US | claimed |
| CN-119838013-A | Application of MLK3 inhibitor in preparation of medicament for treating ischemic cerebrovascular disease | 华中科技大学同济医学院附属同济医院 | 2025-04-18 | — | — | CN | claimed |
| US-20240398848-A1 | MLK-Regulated microRNAs in Angiogenesis and Tumor Development | UNIVERSITY OF MASSACHUSETTS | 2024-12-05 | — | — | US | claimed |
| US-20220218662-A1 | COMBINED MAPK AND NAMPT INHIBITION FOR TREATMENT OF NEURON DEGENERATION | THE JOHNS HOPKINS UNIVERSITY | 2022-07-14 | — | — | US | claimed |
| US-20220211706-A1 | Methods and Compositions for Treating Cancer | UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2022-07-07 | — | — | US | claimed |
| US-11285154-B2 | Methods and compositions for treating cancer | UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2022-03-29 | — | — | US | claimed |
| US-20260146254-A1 | Enhancing Oligonucleotide Immunomodulatory Activity through Dianophore Long-Lasting Modification: Methods and Applications | SEGENA CORPORATION S.A. (UY) | 2026-05-28 | — | — | US | disclosed |
| US-20260146047-A1 | MACROCYCLIC HETEROCYCLE COMPOUNDS AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-05-28 | — | — | US | disclosed |
| US-12637418-B2 | Heterocyclic compounds as antagonist of NMDA | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-05-26 | — | — | US | disclosed |
| CN-122071471-A | Heterocyclic compounds | 武田药品工业株式会社 | 2026-05-22 | — | — | CN | disclosed |
| US-12630509-B2 | Heterocyclic NMDA antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-05-19 | — | — | US | disclosed |
| US-12630534-B2 | 1-((1H-pyrazol-4-yl)methyl)-3-(phenyl)-1,3-dihydro-2H-imidazol-2-one derivatives and related compounds as GPR139 antagonists for the treatment of e.g. depression | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-05-19 | — | — | US | disclosed |
| CN-122010946-A | Heterocyclic compounds | 武田药品工业株式会社 | 2026-05-12 | — | — | CN | disclosed |
| US-11273142-B2 | Treatment for tumors driven by metabolic dysfunction | SYNDEVRX, INC. (US) | 2022-03-15 | — | — | US | disclosed |
| CN-114181136-A | Substituted piperidine compounds and uses thereof | 武田药品工业株式会社 | 2022-03-15 | — | — | CN | disclosed |
| US-11266395-B2 | Devices and methods to provide hands free scleral depression during ophthalmic procedures | Ganihand, LLC (US) | 2022-03-08 | — | — | US | disclosed |
| EP-3956446-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF NLRP3 INFLAMMASOME MEDIATED IL-1BETA DEPENDENT DISORDERS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2022-02-23 | — | — | EP | disclosed |
| US-11246940-B2 | Peptides whose uptake in cells is controllable | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-02-15 | — | — | US | disclosed |
| US-20220040095-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2022-02-10 | — | — | US | disclosed |
| US-11230541-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11230541-B2 | Heterocyclic compound | GRIN1, GRIN2A, GRIN2B | MAP3K11 1880/4885MAP3K9 2726/4885MAP3K10 1972/4885 |
| US-12630509-B2 | Heterocyclic NMDA antagonists | GRIN1, GRIN3A, GRIN2B | MAP3K11 2728/4885MAP3K9 3046/4885MAP3K10 2688/4885 |
| US-11273142-B2 | Treatment for tumors driven by metabolic dysfunction | PCK2, GOT2, PC | MAP3K11 1500/4885MAP3K9 1509/4885MAP3K10 1399/4885 |
| US-12637418-B2 | Heterocyclic compounds as antagonist of NMDA | GRIN1, GRIN3A, GRIN2A | MAP3K11 3449/4885MAP3K9 3736/4885MAP3K10 3189/4885 |
| US-20260146254-A1 | Enhancing Oligonucleotide Immunomodulatory Activity through Dianophore Long-Lasting Modification: Methods and Applications | CD44, ADAR, TLR9 | MAP3K11 4331/4885MAP3K9 4696/4885MAP3K10 4622/4885 |
| US-20260146047-A1 | MACROCYCLIC HETEROCYCLE COMPOUNDS AND USE THEREOF | HCRTR2, HCRTR1, NPY1R | MAP3K11 2633/4885MAP3K9 3299/4885MAP3K10 3246/4885 |
| US-20220040095-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | MAP3K11 2315/4885MAP3K9 3923/4885MAP3K10 3491/4885 |
| US-12630534-B2 | 1-((1H-pyrazol-4-yl)methyl)-3-(phenyl)-1,3-dihydro-2H-imidazol-2-one derivatives and related compounds as GPR139 antagonists for the treatment of e.g. depression | GPR139, OPRL1, GRIN2C | MAP3K11 3686/4885MAP3K9 4213/4885MAP3K10 3366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.